Banco Bradesco SA engages in the provision of financial and insurance services. It operates through Banking, and Insurance segments. The Banking segment ...

Banco Bilbao Vizcaya Argentaria SA engages in the traditional banking businesses of retail banking, asset management, private banking, and wholesale banking.

Enquanto o presidente americano Donald Trump e seus assessores começam a avaliar substitutos para o presidente do Federal ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Novo Nordisk announced this morning that it is ending its partnership with Hims & Hers, which allowed the telehealth provider to sell Novo's blockbuster weight-loss drug, Wegovy.

(RTTNews) - Novo Nordisk's (NVO) Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared to 2.3% ...

CagriSema shows mild-to-moderate side effects in trials Researcher sees benefit to additional weight-loss options Novo Nordisk plans regulatory filing for CagriSema in early 2026 June 22 (Reuters ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ingredient in Ozempic and Wegovy—after failing to pay a routine $450 maintenance ...

In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual $250 maintenance fee on time, but the company could maintain the patent by paying a total of $450.

Lone Star Funds to gain $5.2 billion by selling Novo Banco to French bank BPCE, marking a successful turnaround of Portugal's fourth-largest bank.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee?